Pacira BioSciences (NASDAQ:PCRX) Given New $25.00 Price Target at Barclays

Pacira BioSciences (NASDAQ:PCRX) had its target price reduced by Barclays from $27.00 to $25.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Other analysts have also recently issued research reports about the company. Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Needham & Company LLC reissued a “buy” rating and set a $30.00 price objective on shares of Pacira BioSciences in a report on Friday, January 9th. HC Wainwright reissued a “buy” rating and issued a $38.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Zacks Research lowered Pacira BioSciences from a “hold” rating to a “strong sell” rating in a report on Monday, March 9th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Pacira BioSciences currently has a consensus rating of “Hold” and an average price target of $30.25.

Pacira BioSciences Stock Down 0.8%

Pacira BioSciences stock opened at $23.31 on Thursday. The company has a market capitalization of $943.82 million, a P/E ratio of 155.40 and a beta of 0.21. The firm’s fifty day simple moving average is $21.80 and its 200-day simple moving average is $23.42. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54. Pacira BioSciences has a 1-year low of $18.80 and a 1-year high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.28). The business had revenue of $196.87 million during the quarter, compared to analyst estimates of $201.93 million. Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.91 EPS. Sell-side analysts forecast that Pacira BioSciences will post 2.41 earnings per share for the current fiscal year.

Insider Transactions at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,261 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the completion of the transaction, the insider owned 223,640 shares of the company’s stock, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Lauren Riker sold 4,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the sale, the senior vice president owned 52,313 shares of the company’s stock, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 8,677 shares of company stock valued at $191,980 over the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. lifted its holdings in shares of Pacira BioSciences by 17.8% during the second quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company’s stock worth $84,000 after buying an additional 531 shares during the last quarter. Inspire Investing LLC grew its stake in shares of Pacira BioSciences by 3.2% in the fourth quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock worth $465,000 after acquiring an additional 556 shares during the last quarter. Hantz Financial Services Inc. grew its stake in shares of Pacira BioSciences by 175.4% in the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after acquiring an additional 721 shares during the last quarter. State of Wyoming increased its position in Pacira BioSciences by 7.0% during the fourth quarter. State of Wyoming now owns 11,155 shares of the company’s stock worth $289,000 after acquiring an additional 728 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in Pacira BioSciences by 8.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 10,604 shares of the company’s stock valued at $259,000 after purchasing an additional 785 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.